Harness the Power of HTG's Propietary Transcriptome Panel
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG's RNA platform technologies make the development of life science tools and diagnostics more effective and cost-efficient, enabling researchers to interrogate the entire transcriptome with smaller sample requirements and higher success rates.
The University of Texas MD Anderson Cancer Center
Saint John’s Cancer Institute
Duke University Medical Center
Fundación Instituto Valenciano de Oncologia
Tyrolpath Obrist Brunhuber GmbH
University Hospital Essen
Johannes Wesling Hospital Minden
Alacris Theranostics GmbH
Centre Leon Berard
The Larner College of Medicine at the University of Vermont
Mayo Clinic
Universitätsklinikum Tübingen
Institute of Immunobiology, Kantonsspital St. Gallen
University Hospital Basel
Imperial College London
Featured Publication
Overview of the Design and Performance of the HTG Transcriptome Panel
READ PUBLICATION
HTG Molecular News & Events
HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling…
- Category:
- Press Releases
HTG Molecular Diagnostics Reports Third Quarter 2021 Results
Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz. , Nov. 10, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its…
- Category:
- Press Releases
HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Conference Call on Wednesday, November 10
TUCSON, Ariz. , Nov. 02, 2021 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021…
- Category:
- Press Releases
Resources
Find product information, specifications and gene lists here.
Support
Log in to your account to view technical manuals, package inserts, and other information related to your HTG EdgeSeq system or panels.
Log in to your accountPage last updated November 09, 2021
Ready to get started?
HTG is focused on delivering exceptional molecular profiling products and services. Contact us to find out how our unique technology can benefit you.